$OMER

Borges David J. sold $85K of OMER

Borges David J. (VP, Finance & CAO) sold 5,000 shares of OMEROS CORP (OMER) at $16.95 on 2026-08-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Borges David J.
Published Aug 17, 2026, 11:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 11:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMER
Neutral
high confidence
Mentioned
$OMER
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERNeutralLow
01

Why it matters

The disclosed event is an open-market sale by an officer under a pre-arranged 10b5-1 plan, which typically has limited informational content about near-term fundamentals.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a fundamental repricing without accompanying company news.

03

What to watch

The article provides no context on total insider holdings beyond the post-transaction 0 shares, and it does not indicate whether other insiders sold or whether there were concurrent company-specific catalysts.

Relevance 2/10Novelty 2/10Timing: Form 4 filed 2026-08-17 for a sale dated 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for OMEROS CORP.

Company-level read

Ticker impact

$OMERNeutralHigh confidence
Context

OMEROS CORP disclosed an insider open-market sale by VP, Finance & CAO Borges David J. of 5,000 shares at $16.95 on 2026-08-13.

Expected impact

Likely limited near-term impact; any effect is typically sentiment-only and outweighed by the pre-arranged nature.

Evidence & confidence

The filing specifies a pre-arranged Rule 10b5-1 plan and an open-market sale, which generally reduces interpretive signal versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, some traders may still view insider selling as a mild negative signal, especially if it coincides with other bearish developments not mentioned here.

Key entities

  • OMEROS CORP

    Company subject of the Form 4 insider transaction disclosure.

  • Borges David J.

    VP, Finance & CAO who sold 5,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMERHighAI 8/10

Omeros (OMER) Q2 2026 Earnings Call Transcript

Omeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.

$OMERMed

Omeros Corporation Q2 2026 Earnings Call Summary

Omeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.

$OMERHighAI 9/10

Why is Omeros stock surging today?

Omeros (OMER) shares rose about 17% in pre-open after the company reported Q2 2026 results. Adjusted EPS was $0.02 versus a consensus $0.25 loss, and revenue was $28.5M versus $12.67M expected. YARTEMLEA sales were $32.2M gross, and Omeros reported GAAP net income of $13.2M and first positive operating cash flow.

$OMERMed

OMEROS CORP (OMER): Results of Operations and Financial Condition

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Second Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 12, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second q

$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.